Sanofi (SNYNF)

OTCMKTS · Delayed Price · Currency is USD
92.98
0.00 (0.00%)
Feb 13, 2026, 9:30 AM EST
Market Cap111.71B -16.8%
Revenue (ttm)54.85B +5.5%
Net Income9.17B +40.5%
EPS7.52 +44.2%
Shares Outn/a
PE Ratio12.18
Forward PE9.39
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume68,385
Open92.98
Previous Close92.98
Day's Range92.98 - 92.98
52-Week Range90.05 - 122.03
Beta0.37
RSI45.35
Earnings DateJan 29, 2026

About Sanofi

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, that includes hepati... [Read more]

Sector Healthcare
Founded 1994
Employees 82,878
Stock Exchange OTCMKTS
Ticker Symbol SNYNF
Full Company Profile

Financial Performance

In 2025, Sanofi's revenue was 46.72 billion, an increase of 5.49% compared to the previous year's 44.29 billion. Earnings were 7.81 billion, an increase of 40.52%.

Financial numbers in EUR Financial Statements

News

Sanofi expands Hyd GCC, to host around 5k workers

Hyderabad: In a move that bolsters Hyderabad's rapidly growing stature as a pharma global capability centre, Sanofi Healthcare India has expanded its .

1 day ago - The Times of India

Drugmaker Sanofi to expand India GCC, increase workforce to over 4,500 employees

French drugmaker Sanofi said on Monday it will expand its global capability centre (GCC) in the southern Indian city of Hyderabad, and increase its workforce to more than 4,500 employees.

1 day ago - Reuters

Sanofi: Beyfortus Study Shows Benefit For Infants Beyond First RSV Season

(RTTNews) - Sanofi (SNY) said a universal respiratory syncytial virus immunization program using Beyfortus or nirsevimab was associated with a statistically significant reduction in RSV-related hospit...

1 day ago - Nasdaq

Press Release: Beyfortus study published in The Lancet Infectious Diseases shows benefit for infants beyond first RSV season

Beyfortus study published in The Lancet Infectious Diseases shows benefit for infants beyond first RSV season First study showing that infants immunized against RSV in their first season had fewer RSV...

1 day ago - GlobeNewsWire

Sanofi (SNY) Appoints New CEO Amidst Stock Challenges

Sanofi (SNY) Appoints New CEO Amidst Stock Challenges

4 days ago - GuruFocus

Sanofi Stock Near 52-Week Low As Leadership Shakeup Rattles Investors

Sanofi SA (NASDAQ: SNY) shares are down during Friday’s premarket session as the company faces leadership changes amid ongoing challenges in its drug pipeline. On Thursday, the French drugmaker with ...

4 days ago - Benzinga

Sanofi Stock Near 52-Week Low As Leadership Shakeup Rattles Investors

Sanofi SA (NASDAQ: SNY) shares are down during Friday's premarket session as the company faces leadership changes amid ongoing challenges in its drug pipeline.

4 days ago - Benzinga

Sanofi's new CEO needs to fix drug pipeline and navigate Trump

Sanofi's incoming CEO, 65-year-old Belén Garijo, faces a major task to win over investors, accelerate the French company's stalled drug development pipeline and navigate vaccine scepticism in the Unit...

4 days ago - Reuters

French vaccine maker Sanofi ousts CEO Paul Hudson with Merck boss to take over

French drugmaker Sanofi ousted CEO Paul Hudson on Thursday, ending a six-year tenure marked by a stalled drive to replace blockbuster drugs going off patent and rising pressure from US anti-vaccine po...

4 days ago - Independent Ireland

Sanofi SA (SNY) Stock Price Down 3.43% on Feb 12

Sanofi SA (SNY) Stock Price Down 3.43% on Feb 12

5 days ago - GuruFocus

Sanofi Tumbles After Board Shockingly Ousts CEO Paul Hudson

Sanofi stock skidded Thursday after the pharma giant's board ousted Paul Hudson as CEO, replacing him with Merck KGaA's Belen Garijo.

5 days ago - Investor's Business Daily

Sanofi Shares Fall After CEO Change

5 days ago - The Wall Street Journal

Sanofi (SNY) Appoints Belen Garijo as Incoming CEO

Sanofi (SNY) Appoints Belen Garijo as Incoming CEO

5 days ago - GuruFocus

Leadership Change Announced for Sanofi (SNY)

Leadership Change Announced for Sanofi (SNY)

5 days ago - GuruFocus

Sanofi Shocker: CEO Paul Hudson Out As Board Demands 'Increased Rigor'

Sanofi SA (NASDAQ: SNY) on Wednesday decided not to renew the Director mandate of Paul Hudson . As a result, Paul Hudson's last day as Chief Executive Officer will be on February 17, 2026, after his ...

5 days ago - Benzinga

Who is Sanofi's new CEO Belén Garijo?

French drugmaker Sanofi on Thursday appointed Belén Garijo as its new chief executive after choosing not to renew the mandate of Paul Hudson.

5 days ago - Reuters

Sanofi (SNY) Appoints New CEO, Belén Garijo, to Lead Future Strategy

Sanofi (SNY) Appoints New CEO, Belén Garijo, to Lead Future Strategy

5 days ago - GuruFocus

Sanofi CEO Paul Hudson To Depart; Belén Garijo Named Successor

(RTTNews) - Sanofi (SAN.PA, SNY), a French pharmaceutical and healthcare company, on Thursday announced that the Board of Directors had decided not to renew the director mandate of Chief Executive Off...

5 days ago - Nasdaq

Sanofi appoints Belén Garijo as new CEO after deciding not to renew current CEO Hudson's mandate

French drugmaker Sanofi said on Thursday it had appointed Belén Garijo as its new chief executive after deciding not to renew the mandate of current CEO Paul Hudson.

5 days ago - Reuters

Press Release: Belén Garijo to become Chief Executive Officer of Sanofi

Belén Garijo to become Chief Executive Officer of Sanofi Paris, February 12, 2026. Sanofi's Board of Directors met on February 11, 2026, and decided not to renew the Director mandate of Paul Hudson.

5 days ago - GlobeNewsWire

Sanofi Breaks Above 200-Day Moving Average - Bullish for SNY

In trading on Wednesday, shares of Sanofi (Symbol: SNY) crossed above their 200 day moving average of $49.14, changing hands as high as $49.42 per share. Sanofi shares are currently trading up about 1...

6 days ago - Nasdaq

Sanofi (SNY) Invests $30M in GluBio for Sickle Cell Disease Research

Sanofi (SNY) Invests $30M in GluBio for Sickle Cell Disease Research

6 days ago - GuruFocus

Sanofi: Information concerning the total number of voting rights and shares – January 2026

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement g...

6 days ago - GlobeNewsWire